Absci Corporation (ABSI)
| Market Cap | 1.70B |
| Revenue (ttm) | 1.84M |
| Net Income (ttm) | -118.44M |
| Shares Out | 155.91M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,453,389 |
| Open | 10.02 |
| Previous Close | 10.21 |
| Day's Range | 9.96 - 11.36 |
| 52-Week Range | 2.24 - 11.36 |
| Beta | 2.46 |
| Analysts | Strong Buy |
| Price Target | 12.00 (+10.19%) |
| Earnings Date | Aug 11, 2026 |
About ABSI
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Ket... [Read more]
Financial Performance
In 2025, Absci's revenue was $2.80 million, a decrease of -38.24% compared to the previous year's $4.53 million. Losses were -$115.18 million, 11.7% more than in 2024.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ABSI stock is "Strong Buy." The 12-month stock price target is $12.0, which is an increase of 10.19% from the latest price.
News
Healthcare stocks have become a haven for investors ditching tech
Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.
Absci price target raised to $10 from $4.10 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Absci (ABSI) to $10 from $4.10 and keeps an Equal Weight rating on the shares after the company reported positive interim Phase…
Absci price target raised to $16 from $8 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Absci (ABSI) to $16 from $8 and keeps a Buy rating on the shares. The firm now includes ABS-201 endometriosis sales into…
Absci prices 13.5M shares at $7.41 in public offering
Absci (ABSI) announced the pricing of an underwritten offering of 13,495,277 shares of its common stock at a price of $7.41 per share, before deducting underwriting discounts and commissions. The…
Absci reports Phase 1 data from human trial of ABS-201
Absci (ABSI) reported positive interim Phase 1 data from its first-in-human trial of ABS-201, an investigational anti-prolactin receptor, or PRLR, antibody. The ABS-201 Phase 1 trial is an ongoing, fi...
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts
Absci price target raised to $15 from $10 at Guggenheim
Guggenheim raised the firm’s price target on Absci (ABSI) to $15 from $10 and keeps a Buy rating on the shares after doing a deeper dive into the company’s lead…
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath...
Absci Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Generative AI platforms have enabled rapid, cost-effective drug discovery, with ABS-201 advancing in phase II trials for androgenic alopecia and endometriosis. Preclinical and early clinical data show promising regenerative effects, targeting large unmet needs in hair loss and women's health.
Absci Slides: FY 2026
Absci has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 9, 2026.
Absci Transcript: AGM 2026
The meeting confirmed a quorum, approved the election of two directors, and ratified Ernst & Young as auditor for 2026. No shareholder questions were received, and all proposals passed by the required majority.
Absci initiated with an Outperform at Leerink
Leerink initiated coverage of Absci (ABSI) with an Outperform rating and $12 price target Absci is an AI-native, clinical-stage story, driven by lead asset ABS-20, in Phase 1/2 for androgenetic…
Absci Transcript: Jefferies Global Healthcare Conference 2026
AI-driven drug discovery platform enables rapid, cost-effective development of novel therapies, with ABS-201 advancing in clinical trials for hair loss and endometriosis. Large market opportunities and multiple clinical readouts are expected in the next 24 months.
Absci Slides: FY 2026
Absci has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 3, 2026.
Absci initiated with a Buy at BTIG
BTIG initiated coverage of Absci (ABSI) with a Buy rating and $9 price target The firm projects $2.2B in peak sales for lead internal candidate ABS-201 across androgenetic alopecia and…
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generativ...
Absci price target lowered to $4.10 from $4.20 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Absci (ABSI) to $4.10 from $4.20 and keeps an Equal Weight rating on the shares.
Absci price target raised to $11 from $9 at JonesResearch
JonesResearch analyst Debanjana Chatterjee raised the firm’s price target on Absci (ABSI) to $11 from $9 and keeps a Buy rating on the shares following the Q1 report. The firm…
Absci reports Q1 EPS (19c), consensus (20c)
Reports Q1 revenue $0.2M, consensus $1.41M. Reports Q1 research and development expenses increased to $19.3M, primarily driven by the advancement of internal programs, including direct costs associate...
Absci Earnings Call Transcript: Q1 2026
ABS-201's phase I/IIa trial is on track, with key data readouts expected in 2026 and early 2027. The company is prioritizing high-ROI programs, expanding its prolactin pipeline, and expects its cash runway to last into 2028, while deprioritizing oncology assets.
Absci Earnings release: Q1 2026
Absci released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Absci Quarterly report: Q1 2026
Absci has published its Q1 2026 quarterly earnings report on May 7, 2026.
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from ...
Absci Slides: Corporate presentation
Absci has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.